UroGen PharmaURGN
URGN
About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Employees: 217
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
11% more funds holding
Funds holding: 115 [Q2] → 128 (+13) [Q3]
13.87% less ownership
Funds ownership: 97.45% [Q2] → 83.58% (-13.87%) [Q3]
34% less capital invested
Capital invested by funds: $673M [Q2] → $447M (-$226M) [Q3]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 1 (-2) [Q3]
82% less call options, than puts
Call options by funds: $323K | Put options by funds: $1.83M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
143%
upside
Avg. target
$25
143%
upside
High target
$25
143%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 39% 1-year accuracy 74 / 190 met price target | 143%upside $25 | Buy Maintained | 15 Jan 2025 |
EF Hutton Jason Kolbert 39% 1-year accuracy 74 / 190 met price target | 143%upside $25 | Buy Maintained | 6 Nov 2024 |
Financial journalist opinion
Neutral
Business Wire
5 days ago
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published in the February issue of The Jou.
Neutral
Business Wire
1 month ago
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 35 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first approved product, and the c.
Neutral
Business Wire
1 month ago
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of adults with low-grade, upper tract urothelial cancer (LG-UTUC). Among patients from the OLYMPUS trial who achieved a complete response after primary.
Neutral
Business Wire
1 month ago
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of the Phase 3 ENVISION trial's efficacy and safety results at the Society of Urologic Oncology (SUO) annual meeting in Dallas, TX. These results, published online in the Journal of Urology in October, demonstrate that treatment with investigational therapy UGN-102, a.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
The mean of analysts' price targets for Urogen Pharma (URGN) points to a 209.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Business Wire
1 month ago
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on UGN-102 (mitomycin) for intravesical solution, JELMYTO (mitomycin) for pyelocalyceal solution, and UGN-301(zalifrelimab intravesical solution) will be presented at the Society of Urologic Oncology (SUO) 2024 annual meeting being held in Dallas, Texas from December 4 –.
Neutral
Business Wire
1 month ago
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primar.
Positive
Seeking Alpha
2 months ago
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks from the past week, aiming to spark ideas and discussions among retail investors. Veradigm Inc. is undervalued due to regulatory pressures, but has significant upside potential with strategic buyers potentially paying mid- or high-teens per share. Casey's General Stores has outperformed its peers and the S&P 500 due to its strategic positioning in rural areas and strong operational execution.
Positive
Seeking Alpha
2 months ago
UroGen Pharma: Choice Based On Near Term High Value PDUFA
Urogen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 potentially being the first FDA-approved treatment for low-grade intermediate-risk NMIBC. Urogen's financials show a cash runway of over 2 years, with additional borrowing contingent on timely FDA approval.
Neutral
Seeking Alpha
2 months ago
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Tara Bancroft - TD Cowen Ram Selvaraju - H.
Charts implemented using Lightweight Charts™